What does SS-31 (elamipretide) cost in each channel?
Prices in US dollars at the verification date. Ranges are published list or program prices where a primary source exists; notes say when a figure is a typical market range instead.
| Channel | Price (USD) | Notes |
|---|---|---|
| With insurance | Not published | Rare disease specialty drug covered case by case for Barth syndrome, typically with prior authorization and manufacturer patient support; patient out of pocket cost is not publicly reported. [2] [4] |
| Branded, from a pharmacy | Up to $66,000per month | Forzinity was reported at approval to be priced at up to nearly $800,000 a year, which is up to about $66,000 per month; the manufacturer does not publish a list price. It is dispensed through specialty pharmacy for Barth syndrome only. [1] [2] |
| Compounded pharmacy | Not published | No lawful compounded price. Elamipretide is not on the 503A bulks list, and material sold online as SS-31 for research use is not the approved drug. [3] |
What is the list price of SS-31 (elamipretide)?
Forzinity received accelerated approval in September 2025 for Barth syndrome, an ultra-rare disease, and is priced accordingly. There is no lower cost licensed channel for other uses.
Does insurance cover SS-31 (elamipretide)?
Coverage is limited to Barth syndrome and is negotiated through specialty pharmacy and prior authorization. Off-label longevity or mitochondrial uses are not covered.
What changes the price?
- Ultra-rare disease pricing for a single approved indication
- Prior authorization and specialty pharmacy dispensing
- Manufacturer patient support program
Frequently asked questions
How much does SS-31 (elamipretide) cost without insurance?
About $66,000 per month at the verification date, depending on the channel: branded, from a pharmacy. See the table above for what each figure includes. [1] [2]
Does insurance cover SS-31 (elamipretide)?
Coverage is limited to Barth syndrome and is negotiated through specialty pharmacy and prior authorization. Off-label longevity or mitochondrial uses are not covered. [2] [4]
What is the list price of SS-31 (elamipretide)?
Forzinity received accelerated approval in September 2025 for Barth syndrome, an ultra-rare disease, and is priced accordingly. There is no lower cost licensed channel for other uses. [1] [2]
Related pages
- SS-31 (elamipretide): evidence, legality, and access
- MOTS-c vs SS-31 (elamipretide) (MOTS-c cost)
- Longevity and healthy aging: peptide evidence
- Muscle wasting and sarcopenia: peptide evidence
- Mitochondrial disease and dysfunction: peptide evidence
- Where it is legal to get: peptide law by state
- Full cost index
Sources
- [1]Reuters report via PharmaLive: FDA cleared pricey rare disease drug over reviewer objections (Forzinity priced at up to nearly $800,000 a year)
- [2]FDA prescribing information for Forzinity (elamipretide) injection, 2025 label via Drugs@FDAFDA
- [3]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA
- [4]Medicare.gov: prescription drug coverage (Part D and outpatient drugs)